CytoDyn (CYDY.PK) Plans on Entering Phase I with Flu Vaccine
CytoDyn Inc. (Pink Sheets: CYDY) is a development stage bio-technology company trying to develop 2 primary therapies. First is a trivalent DNA based pre-flu vaccine. In July 2006, the company acquired the exclusive right to develop a DNA based pre-flu vaccine from the University of Massachusetts.The firm hopes to enter Phase I trials sometime within the next 12 months. At this point, no investigational new drug application has been filed. Unlike other viruses, the flu virus changes every year causing an outbreak of seasonal flu. This requires a new vaccine each and every year once the new stain of influenza…